CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics
GET POWR RATINGS... FREE!
CASI POWR Grades
- Value is the dimension where CASI ranks best; there it ranks ahead of 61.39% of US stocks.
- CASI's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- CASI's current lowest rank is in the Quality metric (where it is better than 3.92% of US stocks).
CASI Stock Summary
- The ratio of debt to operating expenses for CASI Pharmaceuticals Inc is higher than it is for about just 7.24% of US stocks.
- As for revenue growth, note that CASI's revenue has grown 131.8% over the past 12 months; that beats the revenue growth of 95.24% of US companies in our set.
- CASI Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -44.5%, greater than the shareholder yield of just 6.36% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CASI Pharmaceuticals Inc are SGLB, PTE, APDN, GTYH, and DCPH.
- Visit CASI's SEC page to see the company's official filings. To visit the company's web site, go to www.casipharmaceuticals.com.
CASI Valuation Summary
- In comparison to the median Healthcare stock, CASI's EV/EBIT ratio is 107.87% lower, now standing at -2.1.
- CASI's price/sales ratio has moved down 51.9 over the prior 243 months.
- CASI's price/sales ratio has moved down 51.9 over the prior 243 months.
Below are key valuation metrics over time for CASI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CASI | 2014-05-28 | NA | 3.6 | -8.2 | -5.8 |
| CASI | 2012-06-15 | 23.1 | 18.5 | -8.1 | -11.6 |
| CASI | 2012-01-20 | 5.3 | 13.1 | -3.5 | -3.9 |
| CASI | 2008-12-05 | 3.1 | 2.8 | -0.9 | -1.3 |
| CASI | 2007-12-14 | 16.5 | 4.1 | -4.8 | -4.7 |
| CASI | 2006-11-13 | 21.7 | 4.2 | -3.2 | -2.9 |
CASI Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at -325.67%.
- Its 4 year revenue growth rate is now at 31312.02%.
- Its 4 year price growth rate is now at 41.46%.
The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 17.471 | -29.253 | -53.729 |
| 2020-12-31 | 15.141 | -25.886 | -48.287 |
| 2020-09-30 | 11.663 | -22.672 | -46.987 |
| 2020-06-30 | 10.208 | -20.59041 | -39.68 |
| 2020-03-31 | 7.537 | -22.65823 | -46.29917 |
| 2019-12-31 | 4.131 | -23.243 | -46.032 |
CASI Price Target
For more insight on analysts targets of CASI, see our CASI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.20 | Average Broker Recommendation | 1.25 (Strong Buy) |
CASI Stock Price Chart Interactive Chart >
CASI Price/Volume Stats
| Current price | $1.24 | 52-week high | $3.90 |
| Prev. close | $1.16 | 52-week low | $1.14 |
| Day low | $1.16 | Volume | 463,100 |
| Day high | $1.24 | Avg. volume | 1,242,649 |
| 50-day MA | $1.48 | Dividend yield | N/A |
| 200-day MA | $2.14 | Market Cap | 173.35M |
CASI Pharmaceuticals, Inc. (CASI) Company Bio
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.
Latest CASI News From Around the Web
Below are the latest news stories about CASI Pharmaceuticals Inc that investors may wish to consider to help them evaluate CASI as an investment opportunity.
Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI)Oppenheimer analyst Leland Gershell assigned a Buy rating to CASI Pharmaceuticals (CASI) today and set a price target of $5.00. The post Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI) appeared first on Smarter Analyst . |
Mizuho Securities Keeps a Buy Rating on CASI Pharmaceuticals (CASI)In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on CASI Pharmaceuticals (CASI), with a price target of The post Mizuho Securities Keeps a Buy Rating on CASI Pharmaceuticals (CASI) appeared first on Smarter Analyst . |
CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple MyelomaROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose |
Need To Know: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Have Been Buying SharesWe've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On... |
CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare ConferenceCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He , Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference |
CASI Price Returns
| 1-mo | -17.33% |
| 3-mo | -27.91% |
| 6-mo | -63.95% |
| 1-year | -35.75% |
| 3-year | -83.08% |
| 5-year | 9.73% |
| YTD | -57.97% |
| 2020 | -4.53% |
| 2019 | -23.13% |
| 2018 | 23.69% |
| 2017 | 182.61% |
| 2016 | 19.79% |
Loading social stream, please wait...